https://www.selleckchem.com/pr....oducts/a-1155463.htm
CYP2C19*2 carriers had an odds of having MACE of 2.51 (95% CI 1.534-4.09) compared with noncarriers (P .001). However, no factors were significantly associated with bleeding (P 0.05). The CYP2C19*2 gene polymorphism contributes to the risk of MACE in dual clopidogrel-treated Uygur population with ACS with or without PCI (percutaneous coronary intervention). These data may provide valuable insights into the genetic polymorphisms affecting clopidogrel metabolism among minority groups in China. The CYP2C19*2 gene polymorphism c
Like
Comment
Share
